We are live on ! Find out more
ALLR

Allarity Therapeutics

11 hedge funds and large institutions have $1.63M invested in Allarity Therapeutics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

728% more capital invested

Capital invested by funds: $197K → $1.63M (+$1.44M)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

10% more funds holding

Funds holding: 1011 (+1)

5.77% more ownership

Funds ownership: 1.29%7.07% (+5.8%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
1
Reduced
1
Closed
6
Calls
Puts
Net Calls
Net Calls Change

ALLR Hedge Fund Activity: Q3 2025 in Review

11 institutional investors reported a position in Allarity Therapeutics (ALLR) for Q3 2025, worth a combined $1.63M — up 728% from $197K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ALLR positions and 6 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Private Advisor Group, opening a new position worth an estimated $350K. The largest seller was XTX Topco, exiting entirely with an estimated $51.5K sold.

  • 11 institutional investors held Allarity Therapeutics (ALLR) as of Q3 2025, up from 10 in Q2 2025.
  • Funds reported $1.63M of Allarity Therapeutics stock for Q3 2025, up 728% quarter-over-quarter.
  • 7 funds opened new Allarity Therapeutics positions in Q3 2025 and 6 closed out, a net change of +1 holder.
  • The largest Allarity Therapeutics buyer in Q3 2025 was Private Advisor Group, an estimated $350K added.
  • The largest Allarity Therapeutics seller in Q3 2025 was XTX Topco, an estimated $51.5K sold.

Based on aggregated 13F filings for Q3 2025.